연구성과로 돌아가기
2020 연구성과 (143 / 270)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Effect of reducibility on the performance of Co-based catalysts for the production of high-calorie synthetic natural gas | Co-based catalysts were developed for the production of high-calorie synthetic natural gas. The Co reduction in Al2O3- and SiO2-supported catalysts prepared with different Co loading, and their catalytic properties for high-calorie methanation were investigated. The CO conversion of the Co/SiO(2)catalysts was superior to that of the Co/ Al(2)O(3)with the same Co loading, due to their better reducibility at 400 degrees C. The activities of both the Al(2)O(3)and SiO2-supported catalysts increased with Co loading, while the growth of hydrocarbon chains decreased as the Co loading increased. As the reduction temperature increased, crystallite size of Co increased in 10Co/SiO2, resulting in decrease of CO conversion and increase of C(2+)selectivity. The highest CO conversion (98.7%) was obtained over 10Co/SiO(2)reduced at 400 degrees C. Moreover, the heating value of the product gas (10,405 kcal/Nm(3)) exceeded the standard heating value without requiring a high reduction temperature (700 degrees C) or a noble metal (Ru). | Kim, Tae Young; Jo, Seong Bin; Lee, Chul Ho; Kang, Suk-Hwan; Kim, Joon Woo; Lee, Soo Chool; Kim, Jae Chang | Kyungpook Natl Univ, Dept Chem Engn, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Adv Energy Technol, Daegu 41566, South Korea; Korea Inst Ind Technol, Ulsan 44413, South Korea; Inst Adv Engn, Yongin 41718, South Korea; Res Inst Ind Sci & Technol, Pohang 37673, South Korea | ; Kim, Yu/L-8480-2017 | 57208461628; 57190754848; 57203804607; 8549491400; 57203324884; 8524020100; 55382762400 | soochool@knu.ac.kr;kjchang@knu.ac.kr; | KOREAN JOURNAL OF CHEMICAL ENGINEERING | KOREAN J CHEM ENG | 0256-1115 | 1975-7220 | 37 | 10 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;ENGINEERING, CHEMICAL | 2020 | 3.309 | 41.6 | 0.31 | 2025-06-25 | 6 | 6 | High-calorie Synthetic Natural Gas (HC-SNG); Cobalt; Reducibility; Light Hydrocarbons; Heating Value | FISCHER-TROPSCH SYNTHESIS; SUPPORTED COBALT CATALYSTS; NI/AL2O3 CATALYSTS; METHANATION; HYDROGENATION; HYDROCARBONS; CO/SIO2; NICKEL; IRON | Cobalt; Heating Value; High-calorie Synthetic Natural Gas (HC-SNG); Light Hydrocarbons; Reducibility | English | 2020 | 2020-10 | 10.1007/s11814-020-0588-0 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | IL-17 promotes osteoblast differentiation, bone regeneration, and remodeling in mice | Bone homeostasis is maintained by concerted actions of bone-forming osteoblasts and bone-resorbing osteoclasts. A wide range of evidence indicates that a proinflammatory cytokine IL-17 promotes osteoclastogenesis. However, the role of IL-17 in osteoblasts is less well-understood. In the current study, the effect of IL-17 on osteogenic differentiation was investigated in mouse calvarial cells. IL-17 stimulated osteoblast differentiation, mineralization, proliferation, motility, and osteoblast-dependent osteoclastogenesis in vitro. The pro-osteogenic role of IL-17 was dependent on Act1 and the generation of reactive oxygen species. In a critical size calvarial defect model, IL-17 significantly augmented bone regeneration. Importantly, IL-17 also remarkably increased bone remodeling and restored osteoclastogenesis in zoledronate-treated mice. Furthermore, IL-17 conspicuously stimulated the formation of lamellar bones. These data not only provide a clue to understand the role of IL-17 in bone metabolism but also suggest possible applications in bone augmentation therapies. (C) 2020 Elsevier Inc. All rights reserved. | Kim, Hyo Jeong; Seo, Seung Jun; Kim, Jae-Young; Kim, Yong-Gun; Lee, Youngkyun | Kyungpook Natl Univ, Sch Dent, Dept Biochem, Daegu 700412, South Korea; Kyungpook Natl Univ, Sch Dent, Inst Hard Tissue & Bone Regenerat, Daegu 700412, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Periodontol, Daegu 700412, South Korea | ; Kim, Ji-Youn/A-5779-2017 | 57203629899; 59056013900; 56812734700; 55622694400; 36062942200 | periokyg@knu.ac.kr;ylee@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 524 | 4 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 1.2 | 2025-06-25 | 35 | 30 | Osteoblast; IL-17; Differentiation; Bone regeneration; Bone remodeling | OSTEOGENIC DIFFERENTIATION; RHEUMATOID-ARTHRITIS; MECHANISMS; INTERLEUKIN-17 | Bone regeneration; Bone remodeling; Differentiation; IL-17; Osteoblast | Animals; Bone Regeneration; Bone Remodeling; Cells, Cultured; Interleukin-17; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Osteogenesis; cell protein; interleukin 17; protein Act1; reactive oxygen metabolite; unclassified drug; zoledronic acid; Il17a protein, mouse; interleukin 17; animal cell; animal experiment; Article; bone metabolism; bone mineralization; bone regeneration; bone remodeling; cell differentiation; cell isolation; cell motility; cell proliferation; cell size; controlled study; genetic transfection; in vitro study; male; micro-computed tomography; mouse; newborn; nonhuman; ossification; osteoblast; osteoclastogenesis; priority journal; protein function; real time polymerase chain reaction; animal; bone development; bone remodeling; C57BL mouse; cell culture; cytology; metabolism; osteoblast | English | 2020 | 2020-04-16 | 10.1016/j.bbrc.2020.02.054 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Maternal high-fructose intake induces hypertension through activating histone codes on the (pro)renin receptor promoter | High-fructose intake induces hypertension via the renal expression of (pro)renin receptor (PRR) that stimulates the expression of sodium/hydrogen exchanger 3, Na/K/2Cl cotransporter 2, and genes of the intrarenal renin-angiotensin system. We hypothesize that maternal high-fructose intake induces hypertension in subsequent generation offspring through activating histone codes on the PRR promoter. Mice dams were offered 20% fructose solution during pregnancy and lactation, while the subsequent 1st to 4th generation offspring were raised without fructose. Blood pressure was measured via tail-cuff method. The mRNA and protein expression were determined using quantitative real-time polymerase chain reaction and western blotting, respectively. Histone modification was evaluated using a chromatin immunoprecipitation assay. Maternal high-fructose intake statistically significantly increased blood pressure in the 1st and 2nd generations of offspring compared to the control group. Expression levels of sodium transporters and PRR were increased in the kidneys of the 1st to 3rd generation offspring. Increased enrichment of active histone codes such as H3Ac and H3K4me2 but decreased enrichment of repressive histone codes such as H3K9me3 and H3K27me3 on the PRR promoter were observed in the 1st to 3rd not the 4th generation. Moreover, there was increased the mRNA expression for histone acetyltransferase and methyl transferases for H3K4 in the 1st and 2nd generation offspring compared to the control group. This study implicates that maternal high-fructose intake induces hypertension in multigenerational offspring through activating histone codes on the PRR promoter. (C) 2020 Elsevier Inc. All rights reserved. | Cho, Hyun Min; Kim, InKyeom | Dept Pharmacol, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Daegu, South Korea; Kyungpook Natl Univ, Dept Biomed Sci, BK21 Plus KNU Biomed Convergence Program, Daegu, South Korea | 57198104843; 7404144630 | inkim@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 527 | 3 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.42 | 2025-06-25 | 10 | 10 | Maternal high fructose; (pro)renin receptor; Epigenetic; Histone modification; Hypertension | EXPRESSION; RESPONSES; PRORENIN; PREVENTS; DJ-1 | (pro)renin receptor; Epigenetic; Histone modification; Hypertension; Maternal high fructose | Animals; Dietary Carbohydrates; Female; Fructose; Histone Code; Hypertension; Male; Maternal Exposure; Mice, Inbred C57BL; Pregnancy; Prenatal Exposure Delayed Effects; Promoter Regions, Genetic; Receptors, Cell Surface; Renin-Angiotensin System; cyclic AMP responsive element binding protein; euchromatic histone lysine n methyltransferase 2; histone; histone acetyltransferase PCAF; histone deacetylase 1; histone deacetylase 2; methyltransferase; prorenin receptor; unclassified drug; cell surface receptor; fructose; prorenin receptor; animal experiment; animal model; animal tissue; Article; blood pressure measurement; chromatin immunoprecipitation; controlled study; female; high-fructose diet; histone modification; lactation; maternal hypertension; maternal nutrition; mouse; nonhuman; polyacrylamide gel electrophoresis; pregnancy; priority journal; protein expression; quantitative analysis; randomized controlled trial; real time polymerase chain reaction; Western blotting; adverse event; animal; C57BL mouse; carbohydrate diet; genetics; histone code; hypertension; male; maternal exposure; prenatal exposure; promoter region; renin angiotensin aldosterone system | English | 2020 | 2020-06-30 | 10.1016/j.bbrc.2020.04.081 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Modulation of chloroplast components and defense responses during programmed cell death in tobacco infected with Pseudomonas syringae | We examined how tobacco plants coordinate chloroplast components and defense responses during Pseudomonas syringae pv. tomato (Pst) infection. Tobacco leaves infiltrated with Pst induced weak necrosis at 24 h post-infiltration (hpi) and severe necrosis at 48 hpi. Membrane damage, as shown by cellular leakage and malondialdehyde, and H2O2 production began to increase at 12 hpi and continuously increased at 24-72 hpi in Pst-infiltrated leaves. Pst infection resulted in decreases in light-harvesting chlorophyll-binding proteins (Lhc), Lhcb transcripts, electron transport rate, and F-v/F-m, indicating the impairment in structure and function of photosystem II. Photochemical quenching, qP, continuously decreased in Pst-infiltrated leaves at 24-48 hpi, whereas nonphotochemical quenching, NPQ exhibited a 2-fold increase at 24 hpi and a decrease at 48 dpi. In response to Pst infection, chlorophyll began to decrease at 48 hpi, whereas levels of protoporphyrin IX (Proto IX), Mg-Proto IX, Mg-Proto methylester, and protochlorophyllide drastically decreased or disappeared as early as 24 hpi. Pst-infiltrated leaves greatly up-regulated the expression of ROS scavenging genes, Fe-SOD, APX, and CATI, as well as defense-related genes, PII, PR1, PR2, PALa, and CHS1. Our study suggests that the modulation of photosynthetic components during pathogen infection, particularly in relation to the fast degradation of photo-sensitizing porphyrin intermediates and the increase in photoprotective NPQ may contribute to attenuating cellular damage in the early stages of programmed cell death induced by Pst. (C) 2020 Elsevier Inc. All rights reserved. | Tran, Bao Quoc; Jung, Sunyo | Kyungpook Natl Univ, Sch Life Sci & Biotechnol, BK21 Plus KNU Creat BioRes Grp, Daegu 41566, South Korea | 57209008094; 7403677383 | sjung@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 528 | 4 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.56 | 2025-06-25 | 9 | 8 | Defense; Photosystem; Porphyrin; Programmed cell death; Pseudomonas syringae | PORPHYRIN BIOSYNTHESIS; OXIDATIVE STRESS; FLUORESCENCE; PLANTS; SIGNALS | Defense; Photosystem; Porphyrin; Programmed cell death; Pseudomonas syringae | Apoptosis; Chloroplasts; Gene Expression Regulation, Plant; Host-Pathogen Interactions; Photosynthesis; Plant Diseases; Pseudomonas syringae; Tobacco; chlorophyll binding protein; iron superoxide dismutase; light harvesting chlorophyll binding protein; magnesium proto methylester; magnesium protoporphyrin IX; pigment; porphyrin; protochlorophyllide; protoporphyrin; unclassified drug; apoptosis; APX gene; Article; bacterial plant disease; CAT1 gene; chloroplast; CHS1 gene; controlled study; defense mechanism; electron transport; Fe SOD gene; gene; gene expression; genetic transcription; membrane damage; necrosis; Nicotiana tabacum; nonhuman; nonphotochemical quenching; oxidative stress; PALa gene; photochemical quenching; photosystem II; PII gene; plant leaf; PR1 gene; PR2 gene; priority journal; Pseudomonas syringae pv. tomato; upregulation; apoptosis; chloroplast; cytology; gene expression regulation; genetics; host pathogen interaction; microbiology; photosynthesis; physiology; plant disease; Pseudomonas syringae; tobacco | English | 2020 | 2020-08-06 | 10.1016/j.bbrc.2020.05.086 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | NAB2-STAT6 fusion protein mediates cell proliferation and oncogenic progression via EGR-1 regulation | Solitary fibrous tumors are rare mesenchymal tumors derived from soft tissues and vascular walls. NAB2-STAT6 fusion gene serves as a marker gene for this disease and consists of the truncated repressor domain of NGFI-A-Binding protein 2 (NAB2) and the intact activation domain of STAT6. In this study, we found that EGR-1 and the proliferation-related EGR-1 target gene IGF2 were upregulated in NIH-3T3 cells transfected with NAB2-STAT6. Additionally, p-Rb (Ser795) and cyclin D1 levels were upregulated, and cell proliferation was also enhanced. We identified that treatment with the IGF2 inhibitor reduced cell proliferation in NIH-3T3 cells transfected with NAB2-STAT6. The oncogenic progression was enhanced in NIH-3T3 cells transfected with NAB2-STAT6 compared with those transfected with the empty vector. Taken together, our study suggests that the NAB2-STAT6 fusion gene is associated with cell proliferation through EGR-1 transcriptional expression and IGF2 can be a drug target for the treatment of solitary fibrous tumors. (C) 2020 Elsevier Inc. All rights reserved. | Park, Ye-Seul; Kim, Hyeng-Soo; Kim, Ju-Heon; Choi, Sung-Hun; Kim, Da-Som; Ryoo, Zae Young; Kim, Jae-Young; Lee, Sanggyu | Kyungpook Natl Univ, BK21 Plus KNU Creat BioRes Grp, Sch Life Sci, Daegu 41566, South Korea; Kyungpook Natl Univ, Inst Life Sci & Biotechnol, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Biochem, Sch Dent, IHBR, Daegu 41940, South Korea | Lee, Jee-Yon/GER-4141-2022; RYOO, ZAEYOUNG/AAQ-1573-2020 | 57215934998; 35112301400; 57196345086; 57215934146; 57215934709; 16937104900; 56812734700; 7601418915 | slee@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 526 | 2 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.99 | 2025-06-25 | 19 | 18 | Solitary fibrous tumor; NAB2-STAT6; EGR-1; IGF2; Chromeceptin | SOLITARY FIBROUS TUMOR; IDENTIFICATION; PATHWAY | Chromeceptin; EGR-1; IGF2; NAB2-STAT6; Solitary fibrous tumor | Animals; Carcinogenesis; Cell Proliferation; Disease Progression; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor II; Mice; NIH 3T3 Cells; Oncogene Proteins, Fusion; Repressor Proteins; Solitary Fibrous Tumors; STAT6 Transcription Factor; Transfection; Up-Regulation; chromeceptin; cyclin D1; early growth response factor 1; fusion protein; NGFI A binding protein 2; protein tyrosine kinase inhibitor; retinoblastoma protein; serine; somatomedin B; STAT6 protein; transcription factor; unclassified drug; early growth response factor 1; Egr1 protein, mouse; IGF2 protein, mouse; NAB2 protein, human; oncoprotein; repressor protein; STAT6 protein; STAT6 protein, human; animal cell; antiproliferative activity; Article; carcinogenesis; cell proliferation; controlled study; drug targeting; fusion gene; human; human cell; IGF2 gene; malignant neoplasm; mouse; NIH 3T3 cell line; nonhuman; priority journal; protein expression; protein phosphorylation; solitary fibrous tumor; transcription regulation; upregulation; animal; carcinogenesis; cell proliferation; disease exacerbation; gene expression regulation; genetic transfection; genetics | English | 2020 | 2020-05-28 | 10.1016/j.bbrc.2020.03.090 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | O-GlcNAcylation of Mef2c regulates myoblast differentiation | Unlike other types of glycosylation, O-GlcNAcylation is a single glycosylation which occurs exclusively in the nucleus and cytosol. O-GlcNAcylation underlie metabolic diseases, including diabetes and obesity. Furthermore,O-GlcNAcylation affects different oncogenic processes such as osteoblast differentiation, adipogenesis and hematopoiesis. Emerging evidence suggests that skeletal muscle differentiation is also regulated by O-GlcNAcylation, but the detailed molecular mechanism has not been fully elucidated. In this study, we showed that hyper-O-GlcNAcylation reduced the expression of myogenin, a transcription factor critical for terminal muscle development, in C2C12 myoblasts differentiation by O-GlcNAcylation on Thr9 of myocyte-specific enhancer factor 2c. Furthermore, we showed that O-GlcNAcylation on Mef2c inhibited its DNA binding affinity to myogenin promoter. Taken together, we demonstrated that hyper-O-GlcNAcylation attenuates skeletal muscle differentiation by increased O-GlcNAcylation on Mef2c, which downregulates its DNA binding affinity. (C) 2020 Elsevier Inc. All rights reserved. | Kim, Han Byeol; Seo, Hyeon Gyu; Son, SeongJin; Choi, Hyeonjin; Kim, Byung Gyu; Kweon, Tae Hyun; Kim, Sunghoon; Pai, Jaeyoung; Shin, Injae; Yang, Won Ho; Cho, Jin Won | Yonsei Univ, Coll Life Sci & Biotechnol, Dept Syst Biol, 50 Yonsei Ro, Seoul 03722, South Korea; Yonsei Univ, Glycosylat Network Res Ctr, 50 Yonsei Ro, Seoul 03722, South Korea; Yonsei Univ, Grad Sch, Interdisciplinary Program Integrated OMICS Biomed, 50 Yonsei Ro, Seoul 03722, South Korea; Yonsei Univ, Integrated Genom Res Ctr Metab Regulat, Inst Genet Sci, Dept Biochem & Mol Biol,Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Leading Edge Res Ctr Drug Discovery & Dev & Metab, Daegu, South Korea; Seoul Natl Univ, Coll Pharm, Med Bioconvergence Res Ctr, Dept Mol Med & Biopharmaceut Sci,Grad Sch Converg, Seoul, South Korea; Yonsei Univ, Dept Chem, 50 Yonsei Ro, Seoul 120752, South Korea | shin, i/JCE-1227-2023; Kim, Sunghoon/AAE-8314-2020 | 56580975100; 57191431354; 57218159117; 57215705927; 55797167500; 57217332000; 7601582514; 36523619900; 57222638474; 55501077800; 14818894600 | chojw311@yonsei.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 529 | 3 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.28 | 2025-06-25 | 7 | 8 | O-GlcNAc; Myoblast differentiation; Mef2c; Myogenin | SKELETAL-MUSCLE; TRANSCRIPTIONAL REGULATION; N-ACETYLGLUCOSAMINE; GLCNAC; MYOGENESIS; GENE; MECHANISMS; EXPRESSION; INJURY | Mef2c; Myoblast differentiation; Myogenin; O-GlcNAc | Acetylglucosamine; Acylation; Animals; Cell Differentiation; Cell Line; Glycosylation; HEK293 Cells; Humans; MEF2 Transcription Factors; Mice; Muscle Development; Muscle, Skeletal; Myoblasts; myocyte enhancer factor 2; myocyte enhancer factor 2c; myogenin; threonine; unclassified drug; Mef2c protein, mouse; myocyte enhancer factor 2; n acetylglucosamine; animal cell; animal experiment; animal model; Article; binding affinity; C2C12 cell line; cell differentiation; controlled study; down regulation; human; human cell; mouse; muscle development; muscle injury; myoblast; nonhuman; o GlcNAcylation; priority journal; promoter region; protein analysis; protein DNA binding; protein expression; protein glycosylation; acylation; animal; cell line; cytology; glycosylation; HEK293 cell line; metabolism; muscle development; myoblast; skeletal muscle | English | 2020 | 2020-08-27 | 10.1016/j.bbrc.2020.06.031 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | PEGylated liposome encapsulating nido-carborane showed significant tumor suppression in boron neutron capture therapy (BNCT) | Boron neutron capture therapy (BNCT) is a binary radiotherapy based on nuclear reactions that occur when boron-10 is irradiated with neutrons, which result in the ejection of high-energy alpha particles. Successful BNCT requires the efficient delivery of a boron-containing compound to effect high concentrations in tumor cells while minimizing uptake in normal tissues. In this study, PEGylated liposomes were employed as boron carriers to maximize delivery to tumors and minimize uptake in the reticuloendothelial system (RES). The water-soluble potassium salt of nido-7,8-carborane, nido-carborane, was chosen as the boron source due to its high boron content per molecule. Nido-carborane was encapsulated in the aqueous cores of PEGylated liposomes by hydrating thin lipid films. Repeated freezing and thawing increased nido-carborane loading by up to 47.5 +/- 3.1%. The average hydrodynamic diameter of the prepared boronated liposomes was determined to be 114.5 +/- 28 nm through dynamic light scattering (DLS) measurement. Globular liposomes approximately 100 nm in diameter were clearly visible in transmission electron microscope (TEM) images. The viability of tumor cells following BNCT with 70 mu M nido-carborane was reduced to 17.1% compared to irradiated control cells, which did not contain boronated liposomes. Confocal microscopy revealed that fluorescently labeled liposomes injected into the tail veins of mice were deeply and evenly distributed in tumor tissues and localized in the cytoplasm of tumor cells. When mice were properly shielded with a 12 mm-thick polyethylene board during in vivo irradiation at a thermal neutron flux of 1.94 x 10(4)/cm(2). sec, almost complete tumor suppression was achieved in tumor models injected with boronated liposomes (21.0 mg B-10/kg). Two BNCT cycles spaced 10 days apart further enhanced the therapeutic anti-tumor effect, even when the dose was lowered to 10.5 mg B-10/kg. No notable weight loss was observed in the tumor models during the BNCT study. (C) 2019 Elsevier Inc. All rights reserved. | Lee, Woonghee; Sarkar, Swarbhanu; Ahn, Heesu; Kim, Jung Young; Lee, Yong Jin; Chang, Yongmin; Yoo, Jeongsoo | Kyungpook Natl Univ, Sch Med, Dept Mol Med, BK21 Plus KNU Biomed Convergence Program, Daegu 41944, South Korea; Korea Inst Radiol & Med Sci, Div Appl RI, Seoul 01812, South Korea | Sarkar, Swarbhanu/GOG-8975-2022; Kim, Kyunghoon/AGO-0079-2022 | 55881469700; 36603493100; 56364974400; 7601371677; 56498070500; 7501840633; 8215136400 | yooj@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 522 | 3 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 1.97 | 2025-06-25 | 38 | 37 | Boron neutron capture therapy; Liposome; Carborane; Radiotherapy | MURINE TUMORS; DELIVERY; CHEMISTRY; ABILITY; DRUGS | Boron neutron capture therapy; Carborane; Liposome; Radiotherapy | Animals; Boron; Boron Neutron Capture Therapy; Cell Line, Tumor; Female; Humans; Isotopes; Liposomes; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; carborane derivative; liposome; polyethylene derivative; potassium salt; boron; Boron-10; isotope; liposome; macrogol; animal cell; animal experiment; animal model; animal tissue; Article; boron neutron capture therapy; cancer inhibition; cancer tissue; cell viability; chemical labeling; colon adenocarcinoma; confocal microscopy; controlled study; female; freeze thawing; hydrodynamics; in vivo study; mouse; nanoencapsulation; neutron radiation; nonhuman; photon correlation spectroscopy; priority journal; reticuloendothelial system; transmission electron microscopy; tumor cell; animal; Bagg albino mouse; chemistry; human; neoplasm; tumor cell line | English | 2020 | 2020-02-12 | 10.1016/j.bbrc.2019.11.144 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Poziotinib suppresses ovarian cancer stem cell growth via inhibition of HER4-mediated STAT5 pathway | Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy, with an overall 5-year survival rate of only 30%. EOC is associated with drug resistance, frequent recurrence, and poor prognosis. A major contributor toward drug resistance might be cancer stem cells (CSCs), which may remain after chemotherapy. Here, we aimed to find therapeutic agents that target ovarian CSCs. We performed a high-throughput screening using the Clinical Compound Library with a sphere culture of A2780 EOCs. Poziotinib, a pan-human epidermal growth factor receptor (HER) inhibitor, decreased sphere formation, viability, and proliferation, and induced G1 cell cycle arrest and apoptosis in ovarian CSCs. In addition, poziotinib suppressed stemness and disrupted downstream signaling of Wnt/beta-catenin, Notch, and Hedgehog pathways, which contribute to many characteristics of CSCs. Interestingly, HER4 was overexpressed in ovarian CSCs and Poziotinib reduced the phosphorylation of STAT5, AKT, and ERK, which are regulated by HER4. Our results suggest that HER4 may be a promising therapeutic target for ovarian CSCs, and that poziotinib may be an effective therapeutic option for the prevention of ovarian cancer recurrence. (C) 2020 Elsevier Inc. All rights reserved. | Lee, Heejin; Kim, Jun Woo; Choi, Dong Kyu; Yu, Ji Hoon; Kim, Jae Ho; Lee, Dong-Seok; Min, Sang-Hyun | DGMIF, New Drug Dev Ctr, 80 Chumbok Ro, Daegu 41061, South Korea; Kyungpook Natl Univ, BK21 Plus KNU Creat BioRes Grp, Sch Life Sci & Biotechnol, Daegu, South Korea; Pusan Natl Univ, Sch Med, Dept Physiol, Yangsan 50612, Gyeongsangnam D, South Korea | Kim, Jae/C-5549-2012; Choi, dongKyu/LKL-2959-2024 | 57202875112; 57215818625; 57215816624; 14526268100; 35268883000; 57210068061; 7202852238 | shmin03@dgmif.re.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 526 | 1 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.71 | 2025-06-25 | 15 | 14 | Cancer stern cells; HER4; Poziotinib; STAT5; Sternness; Wnt/beta-catenin | Cancer stem cells; HER4; Poziotinib; STAT5; Stemness; Wnt/β-catenin | Apoptosis; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Female; G1 Phase; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Ovarian Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-4; Receptors, Notch; Signal Transduction; Spheroids, Cellular; STAT5 Transcription Factor; beta catenin; CD133 antigen; epidermal growth factor receptor 4; kruppel like factor 4; messenger RNA; Notch receptor; poziotinib; protein kinase B; sonic hedgehog protein; STAT5 protein; transcription factor NANOG; Wnt protein; beta catenin; epidermal growth factor receptor 4; ERBB4 protein, human; Notch receptor; poziotinib; protein kinase B; quinazoline derivative; sonic hedgehog protein; STAT5 protein; A2780 cell line; antineoplastic activity; apoptosis; Article; cancer stem cell; cell cycle arrest; cell cycle G1 phase; cell growth; cell proliferation; cell viability; concentration response; controlled study; down regulation; drug efficacy; drug mechanism; drug selectivity; drug targeting; EGFR gene; ERBB2 gene; ERBB4 gene; gene; gene expression; high throughput screening; human; human cell; ovary cancer; priority journal; protein expression; protein phosphorylation; SK-OV-3 cell line; cancer stem cell; cell cycle checkpoint; cell nucleus; drug effect; female; gene expression regulation; genetics; metabolism; multicellular spheroid; ovary tumor; pathology; phosphorylation; protein transport; signal transduction; tumor cell line | English | 2020 | 2020-05-21 | 10.1016/j.bbrc.2020.03.046 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Production of bacterial cellulose from alternative cheap and waste resources: A step for cost reduction with positive environmental aspects | Bacterial cellulose (BC), an important biopolymer, has gained tremendous interest in several fields in the last few decades. Despite having the same chemical structure as plant cellulose, BC is superior in physical appearance and purity, as well as in mechanical, crystallinic, and biological properties for multiple applications. Despite these features, BC has limitations in production cost as well as physiological features. Notable limitations, including a non-bactericidal nature, low biocompatibility, and lack of conductive and magnetic properties, have been compensated through the development of composites using nanomaterials and polymers. Similarly, the limitation associated with cost has been reduced by developing new BC synthesis strategies, designing novel bioreactors, using genetically modified microbial species, and exploring alternative cheap fermentation media. Successful BC production has been reported from the use of industrial, confectionary, municipal and other wastes, including coconut water and fruit juices. Herein, we overview various efforts made thus far in identifying waste byproducts and inexpensive carbon sources for cost-effective BC production. It also provides information about the BC market and selling price, as well as techno-economic analysis of biotechnological BC production. This review article includes findings reported in the last few decades, and we hope it will be of great interest for readers as well as commercial BC producers. | Ul-Islam, Mazhar; Ullah, Muhammad Wajid; Khan, Shaukat; Park, Joong Kon | Dhofar Univ, Coll Engn, Dept Chem Engn, Salalah, Oman; Huazhong Univ Sci & Technol, Dept Biomed Engn, Wuhan 430074, Peoples R China; Sun Yat Sen Univ, Mat Sci Inst, PCFM Lab, Sch Chem, Guangzhou 510275, Peoples R China; Sun Yat Sen Univ, GDHPRC Lab, Sch Chem, Guangzhou 510275, Peoples R China; Kyungpook Natl Univ, Dept Chem Engn, Daegu 41566, South Korea | ; Ullah, Muhammad Wajid/L-9399-2019; Khan, Shaukat/GXH-7589-2022 | 37125198700; 55931394200; 55931035600; 7409933024 | parkjk@knu.ac.kr; | KOREAN JOURNAL OF CHEMICAL ENGINEERING | KOREAN J CHEM ENG | 0256-1115 | 1975-7220 | 37 | 6 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;ENGINEERING, CHEMICAL | 2020 | 3.309 | 41.6 | 1.87 | 2025-06-25 | 119 | 142 | Bacterial Cellulose; Cheap Media; Waste Resources; Low-cost Production | ACETOBACTER-XYLINUM; ENZYMATIC SACCHARIFICATION; POTENTIAL APPLICATION; CARBON SOURCE; FILTER-PAPER; NANOCOMPOSITE; NANOPARTICLES; HYDROLYSIS; SUBSTRATE; OPTIMIZATION | Bacterial Cellulose; Cheap Media; Low-cost Production; Waste Resources | English | 2020 | 2020-06 | 10.1007/s11814-020-0524-3 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Pyk2 downstream of G12/13 pathways regulates platelet shape change through RhoA/p160ROCK | Rho/Rho-kinase downstream of G(12/13) plays an important role in the regulation of calcium-independent platelet shape change. We have previously shown that proline-rich tyrosine kinase 2 (Pyk2) is activated downstream of G(12/13) pathways. In this study, we evaluated the role of Pyk2 in G(12/13)-induced platelet shape change. We used low concentrations of YFLLRNP, a heptapeptide binding to protease-activated receptor 1 (PAR1), or PAR4-activating peptide AYPGKF in the presence of G alpha q inhibitor YM254890 to selectively stimulate G(12/13) pathways. We found that G(12/13)-induced platelet shape change was completely inhibited in the presence of Pyk2 inhibitors AG17 and TAT-Pyk2-CT, suggesting an important role of Pyk2 in platelet shape change. In addition, AYPGKF-induced shape change in Gq -/- platelets was completely inhibited in the presence of AG17 or RhoA/p160(ROCK) inhibitor Y27632, confirming the role of Pyk2 in RhoA-dependent shape change. Furthermore, AYPGKF-induced platelet aggregation and dense granule secretion were inhibited by blocking Pyk2 or RhoA. Finally, G(12/13)-induced myosin phosphatase target subunit 1 (MYPT1) phosphorylation was inhibited by AG17, confirming that Pyk2 regulates RhoA/p160(ROCK) activation in platelets. These results demonstrate that Pyk2 downstream of G(12/13) pathways regulates platelet shape change as well as platelet aggregation and dense granule secretion through the regulation of RhoA/p160(ROCK). (C) 2020 Elsevier Inc. All rights reserved. | Chaudhary, Preeti Kumari; Han, Jeung-Sul; Jee, Youngheun; Lee, Seung-Hun; Kim, Soochong | Chungbuk Natl Univ, Coll Vet Med, Cheongju 28644, South Korea; Kyungpook Natl Univ, Coll Agr & Life Sci, Daegu 41566, South Korea; Jeju Natl Univ, Coll Vet Med, Jeju 63243, South Korea; Jeju Natl Univ, Vet Med Res Inst, Jeju 63243, South Korea | 57205579979; 8277688900; 7005104117; 57203394416; 7601600702 | skim0026@cbu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 526 | 3 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.28 | 2025-06-25 | 3 | 4 | Pyk2; G(12/13) pathways; RhoA; Shape change; Platelets | FOCAL TYROSINE KINASE; ADHESION KINASE; PROTEIN-KINASE; ACTIVATION; THROMBIN; RHO; PHOSPHORYLATION; INTEGRIN; FAMILY; CELLS | G<sub>12/13</sub> pathways; Platelets; Pyk2; RhoA; Shape change | Amides; Animals; Blood Platelets; Blood Specimen Collection; Cell Shape; Disease Models, Animal; Enzyme Inhibitors; Female; Focal Adhesion Kinase 2; GTP-Binding Protein alpha Subunits, G12-G13; Humans; Male; Mice; Oligopeptides; Phosphorylation; Platelet Aggregation; Pyridines; Receptor, PAR-1; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; focal adhesion kinase 2; G12 protein; G13 protein; guanine nucleotide binding protein; heptapeptide; myosin phosphatase target subunit 1; phosphatase; protein p160; proteinase activated receptor 1; proteinase activated receptor 4; RhoA guanine nucleotide binding protein; unclassified drug; 4 (1 aminoethyl) n (4 pyridyl)cyclohexanecarboxamide; alanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanine; amide; enzyme inhibitor; focal adhesion kinase 2; guanine nucleotide binding protein alpha subunit; oligopeptide; proteinase activated receptor 1; pyridine derivative; Rho kinase; RhoA guanine nucleotide binding protein; RHOA protein, human; ROCK1 protein, human; tyrosyl-phenylalanyl-leucyl-leucyl-arginyl-asparaginyl-arginine; animal cell; Article; carboxy terminal sequence; controlled study; enzyme phosphorylation; female; human; human cell; male; mouse; nonhuman; priority journal; protein binding; protein expression; signal transduction; thrombocyte aggregation; thrombocyte shape; animal; blood sampling; cell shape; disease model; drug effect; metabolism; phosphorylation; thrombocyte | English | 2020 | 2020-06-04 | 10.1016/j.bbrc.2020.03.130 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis | Objective: ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI). We report data from the Korean ASTRIS subgroup. Methods: Adult patients with locally advanced or metastatic NSCLC with a confirmed T790M mutation, WHO performance status of 0-2 and prior EGFR-TKI therapy, received osimertinib 80 mg once daily. Efficacy outcomes were overall survival (OS), investigator-assessed response rate (RR) and progression-free survival (PFS), and time to treatment discontinuation (TTD). Results: At data cut-off (20 October 2017), 466 Korean patients were enrolled. Baseline EGFR molecular testing was mainly performed on biopsied tissue (75.1%). Baseline mutations co-occurring with T790M included exon 19 deletions (60.7%) and L858R (32.8%). 1-year OS was 82.7% (OS data not matured at data cut-off). Overall, RR was 71.0%, median PFS was 12.4 months and median TTD was 15.0 months. In patients with/without CNS metastases, RR was 68.0% and 79.6%, respectively; median PFS, 10.8 and 11.0 months, respectively; and median TTD, 11.2 and 14.7 months, respectively. Overall, 31.1% of patients experienced >= 1 adverse event (AE), leading to dose modification (12.0%), discontinuation (5.2%) or death (2.8%). Serious AEs (24.9%) included pulmonary embolism (1.7%), pleural effusion (1.7%), and pneumonia (1.5%). Conclusion: In this real-world subgroup analysis of Korean patients in the ASTRIS study, osimertinib demonstrated comparable clinical efficacy to that attained in the global ASTRIS study and other clinical trials, with no new safety concerns. | Cho, Byoung Chul; Kim, Dong-Wan; Park, Keunchil; Lee, Jong-Seok; Yoo, Seung Soo; Kang, Jin Hyoung; Lee, Sung Yong; Kim, Cheol Hyeon; Jang, Seung Hun; Kim, Young-Chul; Yoon, Hyoung-Kyu; Han, Ji-Youn; Kim, Sang-We | Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Coll Med Seoul, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Div Hematol Oncol, Sch Med, Seoul, South Korea; Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seoungnam, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Guro Hosp, Seoul, South Korea; Korea Canc Ctr Hosp, Dept Internal Med, Seoul, South Korea; Hallym Univ, Dept Internal Med, Sacred Heart Hosp, Anyang, South Korea; Chonnam Natl Univ, Hwasun Hosp, Med Sch, Lung Canc Clin, Jeonnam, South Korea; Catholic Univ Korea, Yeouido St Marys Hosp, Dept Internal Med, Seoul, South Korea; Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea | Cho, ByoungChul/LSL-6088-2024; Park, Keunchil/ABD-5852-2021; Lee, Joo Yong/ADE-2110-2022; Kim, Tae-Hee/AAN-9079-2021; Zhang, Jialiang/HGU-6164-2022; Kang, Jin Hyoung/KYQ-2256-2024; Kim, Yong-Joo/AAK-1840-2021; Kim, Dong-Wan/J-5391-2012 | 7401747804; 56189698600; 7408064384; 8622005400; 56479781600; 56656852000; 56734650000; 57223021245; 7402219050; 35201246200; 57214031690; 18042023400; 49061131600 | swkim@amc.seoul.kr; | CURRENT MEDICAL RESEARCH AND OPINION | CURR MED RES OPIN | 0300-7995 | 1473-4877 | 36 | 3 | SCIE | MEDICINE, GENERAL & INTERNAL;MEDICINE, RESEARCH & EXPERIMENTAL | 2020 | 2.58 | 41.6 | 0.72 | 2025-06-25 | 12 | 10 | Osimertinib; non-small cell lung cancer; NSCLC; EGFR T790M mutation; EGFR-TKI therapy | TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; EGFR-TKI; NSCLC; MUTATION; THERAPY; AZD9291 | EGFR T790M mutation; EGFR-TKI therapy; non–small cell lung cancer; NSCLC; Osimertinib | Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Republic of Korea; Treatment Outcome; afatinib; erlotinib; gefitinib; osimertinib; acrylamide derivative; aniline derivative; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; osimertinib; protein kinase inhibitor; adult; advanced cancer; aged; Article; asthenia; brain infarction; cancer localization; cancer staging; cohort analysis; congestive cardiomyopathy; controlled study; diarrhea; drug efficacy; drug safety; drug withdrawal; dyspnea; female; gastrointestinal disease; gene deletion; heart arrest; human; lung embolism; major clinical study; male; metastasis; multiple organ failure; non small cell lung cancer; outcome assessment; overall survival; pleura effusion; pneumonia; progression free survival; time to treatment; genetics; lung tumor; middle aged; mutation; non small cell lung cancer; South Korea; treatment outcome; very elderly | English | 2020 | 2020-03-03 | 10.1080/03007995.2019.1676708 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Retraction; Retracted Publication | RETRACTION: RETRACTED: Wiener model and extremum seeking control for a CO preferential oxidation reactor with CuO-CeO2 catalyst (vol 48, pg 574, 2015) (Retraction of Vol 48, Pg 574, 2015) | Heo, Jea Pil; Kim, Sin; Lee, Hyun Chan; Kim, Dong Hyun; Lee, Jietae | Kyungpook Natl Univ, Dept Chem Engn, Daegu 41566, South Korea | Kim, Yun Hak/ABF-3331-2021; Kim, Jinkwon/AAR-6729-2021; Lee, Si/ABH-1408-2020 | 57189221315; 55268036600; 57202973815; 55574226279; 7601455194 | jtlee@knu.ac.kr; | KOREAN JOURNAL OF CHEMICAL ENGINEERING | KOREAN J CHEM ENG | 0256-1115 | 1975-7220 | 37 | 11 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;ENGINEERING, CHEMICAL | 2020 | 3.309 | 41.6 | 0 | 2025-06-25 | 1 | 0 | English | 2020 | 2020-11 | 10.1007/s11814-017-0358-9 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||||
| ○ | ○ | Article | Solid-state conversion of metal oleate precursors for the preparation of LiNi1/3Co1/3Mn1/3O2as cathode material for lithium-ion batteries | A solid-state conversion process for the preparation of LiNi1/3Co1/3Mn1/3O2(NCM333) using metal oleate precursors was studied. The low melting points of metal oleate complexes result in a highly homogeneous mixture of Li-, Ni-, Co-, and Mn-oleates before calcination at a high temperature in a solid-state conversion process. The discharge capacity and capacity retention were assessed using a control sample prepared with metal acetate precursors. Cyclic voltammetry and electrochemical impedance spectroscopy showed larger cathodic and anodic peak currents and a lower charge transfer resistance for the coin cell with the cathode prepared from metal oleates than for the cell with the cathode prepared from metal acetates. The superior electrochemical properties of the NCM333 cathode prepared by the solid-state conversion process suggested in this study are attributed to the formation of a perfect R $(3) over bar $m layered structure with a low degree of cation mixing. | Kwak, Dongyub; Lim, Won-Gwang; Shin, Kyuchul; Cheong, In Woo; Lee, Jinwoo; Joo, Jin | Kyungpook Natl Univ, Dept Appl Chem, Daegu 41566, South Korea; Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Daejeon 34141, South Korea | 57217094858; 57188658399; 14030501800; 7006733373; 56007027600; 57189617034 | inwoo@knu.ac.kr;jwlee1@kaist.ac.kr;joojin@knu.ac.kr; | KOREAN JOURNAL OF CHEMICAL ENGINEERING | KOREAN J CHEM ENG | 0256-1115 | 1975-7220 | 37 | 7 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;ENGINEERING, CHEMICAL | 2020 | 3.309 | 41.6 | 0.18 | 2025-06-25 | 4 | 4 | Solid-state Conversion; Lithium Ion Battery; Cathode; Cation Mixing; Layered Structure | ELECTROCHEMICAL CHARACTERISTICS; RATE CAPABILITY; HIGH-POWER; LINI1/3CO1/3MN1/3O2; PERFORMANCE; LI(NI1/3CO1/3MN1/3)O-2; DIFFRACTION; CHALLENGES; OXIDE; GEL | Cathode; Cation Mixing; Layered Structure; Lithium Ion Battery; Solid-state Conversion | English | 2020 | 2020-07 | 10.1007/s11814-020-0537-y | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Structural basis for stereospecificity to D-amino acid of glycine oxidase from Bacillus cereus ATCC 14579 | Glycine oxidase (GO) is an enzyme that catalyzes the oxidation of the primary and secondary amines of various chemicals, including glycine, and the enzyme has been applied in a variety of fields, such as biosensor and genetically modified glyphosate resistance plants. Here, we report that the gene product of BC0747 from Bacillus cereus (BcGO) shows oxidase activity for glycine and small D-amino acids, such as D-proline and D-alanine. We also determined the crystal structure of BcGO complexed with the FAD cofactor at a 2.36 angstrom resolution and revealed how the cofactor binds to the deep pocket of the enzyme. We performed the molecular docking calculation of the glycine substrate to the BcGO structure and identified how the carboxyl- and amine-groups of the D-amino acid are stabilized at the substrate binding site. Structural analysis of BcGO also provided information on the structural basis for the stereospecificity of the enzyme to D-amino acids. In addition, we placed the glyphosate molecule, a plant herbicide, at the substrate binding site, and explained how the mutation of Gly51 to arginine enhances enzyme activity. (C) 2020 Elsevier Inc. All rights reserved. | Seok, Jihye; Kim, Yeo-Jin; Kim, Il-Kwon; Kim, Kyung-Jin | Kyungpook Natl Univ, Sch Life Sci, KNU Creat BioRes Grp, Daehak Ro 80, Daegu 41566, South Korea; Kyungpook Natl Univ, KNU Inst Microorganisms, Daehak Ro 80, Daegu 41566, South Korea | Kim, Kyung-Jin/MVY-3405-2025 | 57216545714; 57203809529; 56547774100; 55510867400 | kkim@knu.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 533 | 4 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.21 | 2025-06-25 | 3 | 3 | Glycine oxidase; Bacillus cereus; D-amino acid; Stereochemistry; Glyphosate | SUBTILIS; PURIFICATION | Bacillus cereus; D-amino acid; Glycine oxidase; Glyphosate; Stereochemistry | Amino Acid Oxidoreductases; Amino Acids; Bacillus cereus; Catalytic Domain; Flavin-Adenine Dinucleotide; Glycine; Kinetics; Models, Molecular; Protein Binding; Stereoisomerism; amino acid; glycine oxidase; oxidoreductase; unclassified drug; amino acid; flavine adenine nucleotide; glycine; glycine oxidase; glyphosate; oxidoreductase; protein binding; Article; Bacillus cereus; bacterial strain; binding affinity; controlled study; crystal structure; crystallization; enzyme activity; enzyme structure; expression vector; hydrophilicity; hydrophobicity; molecular docking; nonhuman; priority journal; protein binding; protein purification; site directed mutagenesis; stereochemistry; stereospecificity; tetramerization; Bacillus cereus; chemistry; enzyme active site; enzymology; kinetics; metabolism; molecular model; stereoisomerism | English | 2020 | 2020-12-17 | 10.1016/j.bbrc.2020.09.093 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Structural basis for the inhibition of PDK2 by novel ATP- and lipoyl-binding site targeting compounds | Pyruvate dehydrogenase kinase (PDK) controls the activity of pyruvate decarboxylase complex (PDC) by phosphorylating key serine residues on the E1 subunit, which leads to a decreased oxidative phosphorylation in mitochondria. Inhibition of PDK activity by natural/synthetic compounds has been shown to reverse the Warburg effect, a characteristic metabolism in cancer cells. PDK-PDC axis also has been associated with diabetes and heart disease. Therefore, regulation of PDK activity has been considered as a promising strategy to treat related diseases. Here we present the X-ray crystal structure of PDK2 complexed with a recently identified PDK4 inhibitor, compound 8c, which has been predicted to bind at the lipoyl-binding site and interrupt intermolecular interactions with the E2-E3bp subunits of PDC. The co-crystal structure confirmed the specific binding location of compound 8c and revealed the remote conformational change in the ATP-binding pocket. In addition, two novel 4,5-diarylisoxazole derivatives, GM10030 and GM67520, were synthesized and used for structural studies, which target the ATP-binding site of PDK2. These compounds bind to PDK2 with a sub-100nM affinity as determined by isothermal titration calorimetry experiments. Notably, the crystal structure of the PDK2-GM10030 complex displays unprecedented asymmetric conformation of human PDK2 dimer, especially in the ATP-lids and C-terminal tails. (C) 2020 Elsevier Inc. All rights reserved. | Kang, Jihoon; Pagire, Haushabhau S.; Kang, Donguk; Song, Yo Han; Lee, In Kyu; Lee, Kang Taek; Park, Chin-Ju; Ahn, Jin Hee; Kim, Jungwook | Gwangju Inst Sci & Technol, Dept Chem, Gwangju 61005, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu 41944, South Korea | Ahn, Jin/C-6122-2019; Kim, Jungwook/AAP-1322-2020; Lee, In-Kyu/AAR-6374-2021; Park, Chin-Ju/B-8198-2018 | 57209097481; 55599893000; 57200659391; 56260651100; 36071537600; 57032024900; 7408414984; 56714432600; 13611462800 | jwkim@gist.ac.kr; | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | BIOCHEM BIOPH RES CO | 0006-291X | 1090-2104 | 527 | 3 | SCIE | BIOCHEMISTRY & MOLECULAR BIOLOGY;BIOPHYSICS | 2020 | 3.575 | 41.6 | 0.07 | 2025-06-25 | 3 | 3 | PDK2; Structure; Anticancer; Compound 8c; Asymmetry | PYRUVATE-DEHYDROGENASE KINASE; CRYSTAL-STRUCTURE; LACTIC-ACIDOSIS; DICHLOROACETATE; METABOLISM; DOMAIN-2; AZD7545 | Anticancer; Asymmetry; Compound 8c; PDK2; Structure | Adenosine Triphosphate; Allosteric Regulation; Binding Sites; Cell Survival; Crystallography, X-Ray; HeLa Cells; Humans; Models, Molecular; Protein Conformation; Protein Kinase Inhibitors; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; adenosine triphosphate; antineoplastic agent; compound 8c; gm 10030; gm 67520; isoxazole; protein serine threonine kinase inhibitor; pyruvate dehydrogenase kinase 2; unclassified drug; adenosine triphosphate; PDK2 protein, human; protein kinase inhibitor; antineoplastic activity; Article; binding affinity; binding site; conformational transition; controlled study; crystal structure; cytotoxicity; drug structure; drug synthesis; enzyme inhibition; enzyme structure; HeLa cell line; human; human cell; isothermal titration calorimetry; molecular interaction; nuclear magnetic resonance; prediction; priority journal; allosterism; binding site; cell survival; chemistry; drug effect; metabolism; molecular model; protein conformation; X ray crystallography | English | 2020 | 2020-06-30 | 10.1016/j.bbrc.2020.04.102 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: